Day 1 - Wednesday, June 13, 2018

8:00
Registration Opens and Refreshments are Served
9:00
Opening Remarks from the Co-Chairs
9:15

OPENING KEYNOTE

Pharma at the Precipice: Navigating the Turbulences of Change
9:45
Gain Insights into the PMPRB Modernization Process and Be Prepared for a New Pricing Landscape
10:30
Networking Break Sponsored by
11:00
Understand Ongoing and Coming Changes at the pCPA to Adjust Your Negotiation Strategy
11:30
To Infinity and Beyond! Developing Effective Pricing Strategies for 2019 and Beyond
12:30
Networking Luncheon
1:30
Putting Theory into Practice: Realizing Your Access Strategy in the Context of Real World Clinical Prescription Decisions
2:15

PANEL

Designing Programs that Support Patients, Provide RWE and are Admissible in Submissions
3:00
Networking Break Sponsored by
3:15
Forecast the Impact of Biosimilars on the Canadian Pharma Landscape to Prepare Accordingly
3:45
Envision a Medical Marijuana Reimbursement Regime in Anticipation of the Legalization of Recreational Use
4:15
Conference Adjourns
Networking Reception Begins

Day 2 - Thursday, June 14, 2018

8:45
Registration Opens and Refreshments are Served
9:15
Opening Remarks from the Co-Chairs
9:30
INESSS’ Role in Quebec’s Strategy for Life Sciences
10:15
Networking and Refreshment Break
10:45
Anticipating Changing Private Payer Cost-Cutting Mechanisms
11:30

PANEL

Leveraging Innovation to Combat Healthcare Spending
12:30
Networking Luncheon
1:30
Personalized Medicine and Its Impact on Patients, the Healthcare System and Pharma
2:15
Pharmacogenomic Testing in BC: A step forward for precision medicine in community pharmacy
3:00
Conference Adjourns

Day 1 - Wednesday, June 13, 2018

8:00
Registration Opens and Refreshments are Served
9:00
Opening Remarks from the Co-Chairs

Kaitlyn Proulx
Managing Director
PDCI Market Access

John-Paul Dowson
Director, Reimbursement Strategy
PDCI Market Access

9:15

OPENING KEYNOTE

Pharma at the Precipice: Navigating the Turbulences of Change

Bernard Munos
Senior Fellow
Milken Institute

  • The digitalization of science and its impact on R&D cost and processes
  • Adapting to payer systems that are at a breaking point
  • Increasing transparency of distribution models in the face of outsider market entry
  • Developing innovation models that function efficiently in a new era

9:45
Gain Insights into the PMPRB Modernization Process and Be Prepared for a New Pricing Landscape

Tanya Potashnik
Director of Policy and Economic Analysis
PMPRB

  • Get the latest on the status of the PMPRB’s consultation on new guidelines and how it anticipates applying the new pricing factors, namely:
    • the schedule of 12 comparator countries, and;
    • cost effectiveness and budget impact thresholds

10:30
Networking Break Sponsored by
11:00
Understand Ongoing and Coming Changes at the pCPA to Adjust Your Negotiation Strategy

Imran Ali
Senior Manager
pan-Canadian Pharmaceutical Alliance

  • Insights into plans for enhanced capacity and what they will mean for the industry landscape moving forward
  • Determine the approach the pCPA will be taking towards biosimilars
  • Updates on a potential governance framework
  • Implications of PMPRB modernization for the functionality of the pCPA

11:30
To Infinity and Beyond! Developing Effective Pricing Strategies for 2019 and Beyond

Imran Ali
Senior Manager
pan-Canadian Pharmaceutical Alliance

Dylan Lamb-Palmer
Manager, Pricing and Data Analytics
PDCI Market Access

Tanya Potashnik
Director of Policy and Economic Analysis
PMPRB

Barbara Jaszewski
Global Pricing and Market Access Consultant

  • Integrating new PMPRB guidelines and pCPA policies into Canadian pricing strategies
  • Understanding the impact of PMPRB health economic guidelines on CADTH/INESSS submissions and pCPA negotiations
  • Implications of reporting PLA rebates to PMPRB
  • Developing timelines for potential PMPRB price adjustments from re-benchmarking
  • Communicating new Canadian policies to global pricing teams
  • Launch sequencing: Impact of lower Canadian prices on Canadian launch

12:30
Networking Luncheon
1:30
Putting Theory into Practice: Realizing Your Access Strategy in the Context of Real World Clinical Prescription Decisions

Dr. Yolande Westra, MD, IM
Assistant Clinical Professor
Department of Medicine, University of Alberta

Jay Mayers
Vice President, Business Development & Cosulting Services
McKesson Specialty Health

  • Understanding levers physicians and patient groups use when deciding to prescribe a drug
  • Circling those levers back to the inclusion criteria in your access strategy
  • Working with physicians to apply real world evidence and track patient outcomes

2:15

PANEL

Designing Programs that Support Patients, Provide RWE and are Admissible in Submissions

Laurie Jenkins
Founder and Senior Patient Advocate
Healthcare Navigators Inc.

Farah Husein
Associate Director - HEOR, Medical Affairs
Astellas Pharma Canada

Brad Millson
Principal, Health Access and Outcomes
IQVIA (Canada)

Moderator:

Bernie Boxill
Director, Patient Support Solutions
STI Technologies

  • Developing a program considered valid and acceptable to patients and payers
  • Generating RWE during clinical trials to include in applications
  • Modifications that incorporate varying specialty drug treatments into programs
  • A look at examples of evidence generation programs occurring in Canada

3:00
Networking Break Sponsored by
3:15
Forecast the Impact of Biosimilars on the Canadian Pharma Landscape to Prepare Accordingly

Mike Woolcock
Senior Vice President Commercial Operations
Apobiologix

  • Presenting market access data for biosimilar reimbursement
  • Guiding principles and prioritization of treatments with CADTH and the enhanced pCPA
  • Lessons learned from international biosimilar access regimes to guide strategy in Canada
  • Impact of SEBs on innovative drugs in the same treatment class

3:45
Envision a Medical Marijuana Reimbursement Regime in Anticipation of the Legalization of Recreational Use

Joan Weir
Director, Health and Disability Policy
CHLIA

  • Next steps for receiving a DIN, or continued use of health spending accounts
  • Extrapolating from current case studies how payers will reimburse cannabis
  • Possibility of inclusion of medical marijuana on managed formularies
  • Use of prior authorization strategies for private payers without Health Canada guidelines

4:15
Conference Adjourns
Networking Reception Begins

Day 2 - Thursday, June 14, 2018

8:45
Registration Opens and Refreshments are Served
9:15
Opening Remarks from the Co-Chairs

Kaitlyn Proulx
Managing Director
PDCI Market Access

John-Paul Dowson
Director, Reimbursement Strategy
PDCI Market Access

9:30
INESSS’ Role in Quebec’s Strategy for Life Sciences

Sylvie Bouchard
Direction du Médicament
INESSS

  • Possible adjustments to the framework
  • Achieving time frames similar to CADTH
  • Access to medication from the perspective of INESSS

10:15
Networking and Refreshment Break
10:45
Anticipating Changing Private Payer Cost-Cutting Mechanisms

Barbara Martinez
National Practice Leader, Drug Benefits Solutions
Great West Life

  • A comparison of different approaches being taken in the market place, such as traditional vs. value or risk-based reimbursement
  • Pointers for formulary negotiations in an era of price pressures
  • Effects of public reimbursement trends on the private payer landscape
  • What is on employers minds with respect to managing drug plans
  • What are the three key drug plan management techniques that employers will use to manage drug spending in today’s environment

11:30

PANEL

Leveraging Innovation to Combat Healthcare Spending

Christina Archer
Country Head, Canada; PDG Site Head, Mississauga
Roche

Paul Grootendorst
Associate Professor, Leslie Dan Faculty of Medicine and School of Public Policy and Governance
University of Toronto

  • R&D as a cost saver, rather than a cost driver through prevention and better health outcomes
  • Considering new technologies, such as 3D printing to reduce production and distribution costs
  • Developing new supply chain and distribution models to mitigate current inefficiencies
  • Understanding life sciences’ potential in Canada for growth in terms of employment, and the economy
  • International trends of innovation in a price pressured context and its effect on the industry

12:30
Networking Luncheon
1:30
Personalized Medicine and Its Impact on Patients, the Healthcare System and Pharma

Brian Jahns
SVP, Commercial and Business Development
Trillium Therapeutics

  • Improving clinical decision-making and maximizing positive health outcomes
  • Anticipating and preventing disease through genetic diagnostics to spare patient suffering and reduce cost of treatment
  • Leveraging health data from home genetic testing kits, wearables and EHRs

2:15
Pharmacogenomic Testing in BC: A step forward for precision medicine in community pharmacy

Bryce Wong
General Manager
RxOme

  • Initial results from the Genomics for Precision Drug Therapy in the Community Pharmacy research study in BC
  • How pharmacogenomics can improve patient outcomes and create cost savings
  • Pharmacogenomics in the Canadian healthcare context

3:00
Conference Adjourns